

# Gilead Sciences Inc

**62.17** Usd  
-1.82%

ISIN: US3755581036  
Ticker: GILD

Sector: Biotechnology  
Stock exchange: NASDAQ  
Market capitalization: 77.97 Billion

**Key Metrics:**

Performance YTD: -4.32%  
Estimated 2020 P/E: 8.97

Earning per share: 4.24  
Price to book: 3.4

Net Debt: 4.74 B  
Return on Equity: -0.013

## Fundamental analysis summary

The presentation of the earnings should arrive on October 22 with an estimate of USD 1.97 per share, share which would represent a growth of about 10% YoY. It is necessary to know that in Q2 2020 they saw a decline in their net Non-GAAP growth income of 36% YoY mainly due to coronavirus. In terms of valuation, P/E of about 10 compared to 26 in the industry. In Q3 2020, one can hope for a resumption of HCV (hepatitis B) treatments that had contributed to the decline in revenues. It should be noted that Gilead has a history of disappointing earnings estimates for Q3. It seems to me even harder for Gilead to beat estimates this year.

## Technical analysis summary

The share price is effectively at its lowest since 2013. Most of the analysts see a price between USD 75 and 88.

## Chart - Year To Date

